Juvenile Arthritis News

Antares Pharma announced it will pair with LEO Pharma to market its single-dose, disposable auto-injector containing methotrexate to dermatologists for treating adults with severe recalcitrant psoriasis.

Cards designed to facilitate shared decision making on medications have been well accepted by patients with juvenile idiopathic arthritis, their parents and clinicians, according to research presented at the American College of Rheumatology annual meeting in San Diego.

SAN DIEGO — A majority of patients with polyarticular juvenile idiopathic arthritis achieved clinical inactive disease within 1 year of receiving aggressive therapy, according to research presented at the American College of Rheumatology annual meeting.

SAN DIEGO — Levels of disease activity and physical disability have progressively declined during the past 25 years for children with juvenile idiopathic arthritis, according to research being presented at the American College of Rheumatology annual meeting.

The FDA has approved a single-dose, disposable auto-injector containing methotrexate for treating patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis or psoriasis, according to Antares Pharma.

Strict etiology classifications and close cooperation between pediatric rheumatologists and ophthalmologists contributed significantly to early inflammation control and long-term prognosis of pediatric uveitis, according to a retrospective data analysis.

Patients with later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis experienced very good 2-year outcomes, according to study results.

Children with juvenile idiopathic arthritis who were in remission after treatment had a different gene expression compared with healthy controls, according to recent study results.

The European Commission has approved canakinumab for treating active systemic juvenile idiopathic arthritis in patients aged 2 years and older who experience inadequate response to nonsteroidal anti-inflammatory drugs and systemic corticosteroids, Novartis announced.

Children with juvenile idiopathic arthritis who were in remission after treatment had a different gene expression compared with healthy controls, according to recent study results.